News | December 19, 2025
Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The move strengthens GBL’s clinical-stage presence in the United States
Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
The companies aim to expand treatment options for millions living with metabolic disorders
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
Captured microbes are then neutralized on engineered microbicidal surfaces
Growing patent filings and tier-2 innovators reflect expanding national research base
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Subscribe To Our Newsletter & Stay Updated
